VEGFA and Miyoshi myopathy: It has been demonstrated that Bortezomib attenuated the hypoxic induction of erythropoietin and VEGF at sub nanomolar concentrations in MM and liver cancer by promoting the interaction between the C-TAD domain of HIF-1α and FIH [209].